Professor Eric Quinton Klug shared his insights on the LIBerate-HR trial. Among patients at high or very high risk for a heart attack or stroke, the addition of the investigational drug lerodalcibep to standard cholesterol-lowering medication for one year reduced LDL, or "bad" cholesterol, levels by more than half on average, compared with a placebo. In addition, 90% of patients treated with lerodalcibep, versus 16% of those on placebo, attained the newer, more stringent guideline-recommended LDL targets set by the American College of Cardiology and other expert organizations.

Video: https://medicaldigest.org/scientific-contents/interview:lerodalcibep-reduces-ldl-cholesterol-over-50-high-risk-patients

David Austin, the study's lead author shared his insights on the PROACT trial. Patients who took the ACE inhibitor enalapril while undergoing cancer treatment with high-dose anthracycline chemotherapy did not show any difference in troponin T levels at one month after their last chemotherapy dose compared with those who did not take it, according to results from the PROACT study presented during a Late-Breaking Clinical Trial session at ACC.24 in Atlanta.

Video: https://medicaldigest.org/scientific-contents/interview:proact-do-ace-inhibitors-help-prevent-cardiotoxicity-patients-treated-breast-cancer-or-lymphoma

Professor Gregg W. Stone shared his insights on the ULTIMATE-DAPT study. Ticagrelor monotherapy following one month of dual antiplatelet therapy (DAPT) outperforms 12-month DAPT (aspirin and ticagrelor) post PCI for reducing clinically meaningful bleeding with no increased thrombotic risk.

Video: https://medicaldigest.org/scientific-contents/interview:ultimate-dapt-most-patients-acs-can-safely-stop-aspirin-one-month-post-pci

Professor Javed Butler shared his insights on the EMPACT-MI study. The SGLT2 inhibitor empagliflozin did not lower the risk of a first hospitalization for heart failure or death from any cause among patients with an increased risk for HF following acute myocardial infarction, according to the results of the EMPACT-MI study.

Video: https://medicaldigest.org/scientific-contents/interview:empact-mi-empagliflozin-post-mi-does-not-lower-risk-first-hf-hospitalization-death

Professor Steven E. Nissen shared his insights on the TACTiC study, presented during a Late-Breaking Clinical Trial session at ACC.24. The study proved that the method improves lipid control and adherence.

Video: https://medicaldigest.org/scientific-contents/interview:outcomes-after-technology-assisted-nonprescription-rosuvastatin-administration-tactic-trial

ACC President B. Hadley Wilson shared his insights on Late-Breaking Clinical Trials I, presented during at ACC.24:

- RELIEVE-HF: Does Impact of Interatrial Shunting Differ By HF Type?

- EMPACT-MI: Empagliflozin Post MI Does Not Lower Risk of First HF Hospitalization, Death

- AEGIS-II: CSL112 Associated With Lower Rates of CV Death, MI

Video: https://medicaldigest.org/scientific-contents/interview:joint-american-college-cardiologyjournal-american-college-cardiology-late-breaking-clinical-trials

Professor Robert Roswell shared his insights on the DanGer Shock trial. Implantation of the Impella CP micro-axial flow pump in the hours after a heart attack significantly increased the rate of survival at six months among people suffering cardiogenic shock, according to a study presented at the American College of Cardiology's Annual Scientific Session.

Video: https://medicaldigest.org/scientific-contents/interview:percutaneous-transvalvular-micro-axial-flow-pump-infarct-related-cardiogenic-shock

Dr. Yakubu Bene-Alhasan shared his insights on the large study that adds to growing body of evidence that vaping may harm the heart. People who use e-cigarettes are significantly more likely to develop heart failure compared with those who have never used them, according to one of the largest prospective studies to date investigating possible links between vaping and heart failure.

Video: https://medicaldigest.org/scientific-contents/interview:study-links-e-cigarette-use-higher-risk-heart-failure

We asked Professor Stefan N. Symeonides, one of the authors of the KEYNOTE-564 study, about the trial and the new data presented on overall survival at ASCO GU 2024.

Adjuvant treatment with pembrolizumab has significantly improved overall survival in patients with clear cell renal cell carcinoma who are at high risk of recurrence after surgery, according to an updated analysis of the KEYNOTE-564 trial.

Video: https://medicaldigest.org/scientific-contents/standalonecontent:overall-survival-results-keynote-564

We asked Professor David F. McDermott, investigator of the KEYNOTE-564 study, about the trial and the new data presented on overall survival at ASCO GU 2024.

Video: https://medicaldigest.org/scientific-contents/standalonecontent:overall-survival-results-keynote-564-adjuvant-pembrolizumab-versus-placebo-renal-cell-carcinoma